Editing Plan for an Integral Clinical Trial
Warning: You are not logged in. Your IP address will be publicly visible if you make any edits. If you log in or create an account, your edits will be attributed to your username, along with other benefits.
The edit can be undone.
Please check the comparison below to verify that this is what you want to do, and then save the changes below to finish undoing the edit.
Latest revision | Your text | ||
Line 27: | Line 27: | ||
! Process/Parameter || How common in ALS? || Effect of Manipulation || Candidate Substances | ! Process/Parameter || How common in ALS? || Effect of Manipulation || Candidate Substances | ||
|- | |- | ||
− | | [[Neuroinflammation]] || General || Reduction is probably beneficial; M2 state of microglia should be promoted{{#pmid:28790913|geloso2017}}. || [[3nB]], [[Baicalin]], [[Curcumin]], [[Ibuprofen]], [[Luteolin]], [[Magnolia bark extract]], [[Peony root extract]], [[Spirulina]], [[Trimethylglycine (TMG)]], [[Vitamin D3]] | + | | [[Neuroinflammation]] || General || Reduction is probably beneficial; M2 state of microglia should be promoted{{#pmid:28790913|geloso2017}}. || [[3nB]], [[Baicalin]], [[Curcumin]], [[Ibuprofen]], [[Luteolin]],[[Magnolia bark extract]], [[Peony root extract]], [[Spirulina]], [[Trimethylglycine (TMG)]], [[Vitamin D3]] |
|- | |- | ||
| [[Mitochondrial dysfunction]] || || || [[Acetyl L-carnitine (ALCAR)]], [[European milk thistle extract]], [[MitoQ]], [[PQQ]], [[R Alpha Lipoic Acid (R-ALA)]], [[Ubiquinol]] | | [[Mitochondrial dysfunction]] || || || [[Acetyl L-carnitine (ALCAR)]], [[European milk thistle extract]], [[MitoQ]], [[PQQ]], [[R Alpha Lipoic Acid (R-ALA)]], [[Ubiquinol]] | ||
− | |||
− | |||
|- | |- | ||
| [[Glutamate|Glutamate toxicity]] || || || [[Acetyl L-carnitine (ALCAR)]], [[Alcohol]], [[Inosine]], [[Magnesium]], [[Methylcobalamin]], [[Pycnogenol]], [[R Alpha Lipoic Acid (R-ALA)]], Riluzole | | [[Glutamate|Glutamate toxicity]] || || || [[Acetyl L-carnitine (ALCAR)]], [[Alcohol]], [[Inosine]], [[Magnesium]], [[Methylcobalamin]], [[Pycnogenol]], [[R Alpha Lipoic Acid (R-ALA)]], Riluzole | ||
Line 37: | Line 35: | ||
| [[HSF1|Heat shock protein inducers]] || Misfolded proteins are a fundamental hallmark of ALS. || Heat shock response assists in proper folding of the proteins and contributes to disaggregation{{#pmid:28724966|wang2017}} of misfolded ones. || [[Curcumin]], [[Peony root extract]] | | [[HSF1|Heat shock protein inducers]] || Misfolded proteins are a fundamental hallmark of ALS. || Heat shock response assists in proper folding of the proteins and contributes to disaggregation{{#pmid:28724966|wang2017}} of misfolded ones. || [[Curcumin]], [[Peony root extract]] | ||
|- | |- | ||
− | | Glutathione support || || || [[TUDCA (tauroursodeoxycholic acid)]], [[European milk thistle extract | + | | Glutathione support || || || [[TUDCA (tauroursodeoxycholic acid)]], [[European milk thistle extract]], [[R Alpha Lipoic Acid (R-ALA)]], [[Selenium]], [[N-Acetyl-cysteine (NAC)]],[[Trimethylglycine (TMG)]] |
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
− | | [[Homocysteine]] || Homocysteine level correlates with disease progression. | + | | [[Homocysteine]] || Homocysteine level correlates with disease progression.{{#pmid:19551535|zoccolella2010}} The effect is possibly due to oxidative stress (via NMDA receptor stimulation {{#pmid:26500495|bukharaeva2015}}) and excitotoxicity. || At least short-term reduction of Hcy with methylcobalamin improves compound ation potentials in ALS patients.{{#pmid:19551535|zoccolella2010}} || [[Methylcobalamin]], [[Folic acid]], [[Trimethylglycide (TMG)]], [[N-Acetyl-cysteine (NAC)]] |
|} | |} | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
== References == | == References == |